Epygen Biotech Gets Funding From Govt For New Affordable Covid Vaccine

The company said it has received funding to initiate the Phase I and Phase II trials of an indigenous affordable Receptor-Binding Domain (RBD) based vaccine against the present and future SARS-CoV–2 variants.

Epygen Biotech on Monday said it has received a funding of Rs 24 crore from the Department of Biotechnology to initiate trials for a new COVID vaccine.

With an anticipated price point of less than Rs 150 per dose, this will be the first time an Indian company will be able to adopt the highly productive C1-cell protein production platform, which has been demonstrated by the scientists at the European Union Zoonotic Anticipation and Preparedness Initiative (ZAPI) program, Epygen Biotech said in a statement.

The company said it has received funding to initiate the Phase I and Phase II trials of an indigenous affordable Receptor-Binding Domain (RBD) based vaccine against the present and future SARS-CoV–2 variants.